BridgeMD
New treatment option for Cancer
Official title DOAC - Dosing Options in AntiCoagulation Prophylaxis
ClinicalTrials.gov ID: NCT07005024
What this study is testing
What is Apixaban 2.5 mg twice daily?
Apixaban 2.5 mg twice daily is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Diagnosed with an active solid tumor or lymphoma
- Starting a new systemic cancer treatment or changing cancer treatment
- Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
- Not currently receiving therapeutic anticoagulation
You likely can't join if
- Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
- Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)
- Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
- Platelet count \< 50,000/µL
- Creatinine clearance \< 25 mL/min
- Life expectancy \< 3 months
See the full eligibility criteria
- Age ≥ 18 years
- Diagnosed with an active solid tumor or lymphoma
- Starting a new systemic cancer treatment or changing cancer treatment
- Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
- Not currently receiving therapeutic anticoagulation
- Able to provide informed consent
- Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
- Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)
- Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
- Platelet count \< 50,000/µL
- Creatinine clearance \< 25 mL/min
- Life expectancy \< 3 months
- Pregnant or breastfeeding
- Inability to comply with study procedures
The study team makes the final eligibility decision.
Where it's taking place
- Burlington, Vermont, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Burlington, Vermont, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.